A recent study led by Xue, Zhou and Chen evaluated sequential PD‑1 inhibitor therapy as consolidation following CD19 CAR‑T in relapsed or refractory non‑Hodgkin lymphoma and reported enhanced outcomes. The research suggests checkpoint blockade administered after CAR‑T may deepen responses and extend disease control in a difficult‑to‑treat population. PD‑1 inhibitors are immune checkpoint drugs that reinvigorate T cells; the study positions consolidation immunotherapy as a tactical option to augment cellular therapy durability. Authors called for larger, controlled trials to define timing, patient selection and safety signals for combined approaches.